Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/29956
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | |
dc.contributor.author | GRATIVVOL, Ronnyson Susano | |
dc.contributor.author | CAVALCANTE, Wagner Cid Palmeira | |
dc.contributor.author | CASTRO, Luiz Henrique Martins | |
dc.contributor.author | NITRINI, Ricardo | |
dc.contributor.author | SIMABUKURO, Mateus Mistieri | |
dc.date.accessioned | 2019-01-17T13:33:53Z | - |
dc.date.available | 2019-01-17T13:33:53Z | - |
dc.date.issued | 2018 | |
dc.identifier.citation | CURRENT ONCOLOGY REPORTS, v.20, n.11, article ID 92, 11p, 2018 | |
dc.identifier.issn | 1523-3790 | |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/29956 | - |
dc.description.abstract | The disorders of the central nervous system associated with cancer by remote immune-mediated mechanisms are a heterogeneous group. These disorders encompass the classic paraneoplastic disorders and the recently recognized autoimmune encephalitis associated with antibodies against neuronal cell surface or synaptic proteins that occur with or without cancer association. In the last decade, the new surge of interest in neuronal diseases associated with anti-neuronal antibodies led to the rapid discovery of new forms of disease that have different manifestations and were not previously suspected to be immune mediated. The recognition of these syndromes is important because it may lead to early detection of an underlying malignancy and prompt initiation of treatment, improving chances for a better outcome. | eng |
dc.description.sponsorship | FAPESP | |
dc.description.sponsorship | Novartis | |
dc.language.iso | eng | |
dc.publisher | SPRINGER | eng |
dc.relation.ispartof | Current Oncology Reports | |
dc.rights | restrictedAccess | eng |
dc.subject | Limbic encephalitis | eng |
dc.subject | Onconeuronal antibodies | eng |
dc.subject | Paraneoplastic neurological syndromes | eng |
dc.subject | Paraneoplastic encephalomyelitis | eng |
dc.subject | Paraneoplastic cerebellar degeneration | eng |
dc.subject | Autoimmune encephalitis | eng |
dc.subject | Stiff person syndrome | eng |
dc.subject | Progressive encephalomyelitis with rigidity and myoclonus | eng |
dc.subject | Opsoclonus-myoclonus syndrome | eng |
dc.subject | Morvan syndrome | eng |
dc.subject | Ophelia syndrome | eng |
dc.subject | N-methyl-d-aspartate receptor (NMDAR) encephalitis | eng |
dc.subject | Anti-AMPA receptor (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) encephalitis | eng |
dc.subject | Anti-GABAbR (gamma-aminobutyric acid receptor-B) encephalitis | eng |
dc.subject | Anti-leucine-rich glioma-inactivated protein 1 (LGI1) encephalitis | eng |
dc.subject | Anti-Caspr2 encephalitis (contactin-associated protein-like 2) | eng |
dc.subject | Anti-glycine receptor (GlyR) antibodies | eng |
dc.subject | Anti-mGluR5 (metabotropic glutamate receptor 5) | eng |
dc.subject | Anti-mGLUR1 (metabotropic glutamate receptor 1) | eng |
dc.subject | Anti-Hu antibodies | eng |
dc.subject | Anti-Ma2 antibodies | eng |
dc.subject | Anti-DNER (Delta | eng |
dc.subject | Notch-like epidermal growth factor-related receptor) antibodies | eng |
dc.subject | Anti-CV2/CRMP5 antibodies | eng |
dc.subject.other | nmda receptor encephalitis | eng |
dc.subject.other | encephalomyelitis sensory neuronopathy | eng |
dc.subject.other | calcium-channel antibodies | eng |
dc.subject.other | eaton myasthenic syndrome | eng |
dc.subject.other | stiff-person syndrome | eng |
dc.subject.other | cell lung-cancer | eng |
dc.subject.other | efns task-force | eng |
dc.subject.other | cerebellar degeneration | eng |
dc.subject.other | limbic encephalitis | eng |
dc.subject.other | glutamate-receptor | eng |
dc.title | Updates in the Diagnosis and Treatment of Paraneoplastic Neurologic Syndromes | eng |
dc.type | article | eng |
dc.rights.holder | Copyright SPRINGER | eng |
dc.identifier.doi | 10.1007/s11912-018-0721-y | |
dc.identifier.pmid | 30415318 | |
dc.subject.wos | Oncology | eng |
dc.type.category | review | eng |
dc.type.version | publishedVersion | eng |
hcfmusp.description.articlenumber | 92 | |
hcfmusp.description.issue | 11 | |
hcfmusp.description.volume | 20 | |
hcfmusp.origem | WOS | |
hcfmusp.origem.id | WOS:000449883900003 | |
hcfmusp.origem.id | 2-s2.0-85056347900 | |
hcfmusp.publisher.city | NEW YORK | eng |
hcfmusp.publisher.country | USA | eng |
hcfmusp.relation.reference | Arino H, 2016, NEUROLOGY, V87, P759, DOI 10.1212/WNL.0000000000003009 | eng |
hcfmusp.relation.reference | Armangue T, 2016, JAMA NEUROL, V73, P417, DOI 10.1001/jamaneurol.2015.4607 | eng |
hcfmusp.relation.reference | Bataller L, 2001, BRAIN, V124, P437, DOI 10.1093/brain/124.2.437 | eng |
hcfmusp.relation.reference | Brain WR, 1965, REMOTE EFFECTS CANC | eng |
hcfmusp.relation.reference | Carvajal-Gonzalez A, 2014, BRAIN | eng |
hcfmusp.relation.reference | CAVINESS JN, 1995, MOVEMENT DISORD, V10, P22, DOI 10.1002/mds.870100106 | eng |
hcfmusp.relation.reference | CORSELLIS JA, 1968, BRAIN, V91, P481, DOI 10.1093/brain/91.3.481 | eng |
hcfmusp.relation.reference | Dalakas MC, 2009, CURR TREAT OPTION N, V11, P102, DOI 10.1007/s11940-009-0013-9 | eng |
hcfmusp.relation.reference | Dale RC, 2009, ANN NEUROL, V66, P704, DOI 10.1002/ana.21807 | eng |
hcfmusp.relation.reference | DALMAU J, 1991, NEUROLOGY, V41, P1757, DOI 10.1212/WNL.41.11.1757 | eng |
hcfmusp.relation.reference | Dalmau J, 2004, BRAIN, V127, P1831, DOI 10.1093/brain/awh203 | eng |
hcfmusp.relation.reference | DALMAU J, 1992, MEDICINE, V71, P59, DOI 10.1097/00005792-199203000-00001 | eng |
hcfmusp.relation.reference | Dalmau J, 2012, BRAIN, V135, P1650, DOI [10.1093/brain/aws064, DOI 10.1093/BRAIN/AWS064] | eng |
hcfmusp.relation.reference | Dalmau J, 2007, ANN NEUROL, V61, P25, DOI 10.1002/ana.21050 | eng |
hcfmusp.relation.reference | Dalmau J, 2018, NEW ENGL J MED, V378, P840, DOI 10.1056/NEJMra1708712 | eng |
hcfmusp.relation.reference | Dalmau J, 2011, LANCET NEUROL, V10, P63, DOI 10.1016/S1474-4422(10)70253-2 | eng |
hcfmusp.relation.reference | Darnell RB, 2003, NEW ENGL J MED, V349, P1543, DOI 10.1056/NEJMra023009 | eng |
hcfmusp.relation.reference | de Graaff E, 2012, ANN NEUROL, V71, P815, DOI 10.1002/ana.23550 | eng |
hcfmusp.relation.reference | Gable MS, 2012, CLIN INFECT DIS, V54, P899, DOI 10.1093/cid/cir1038 | eng |
hcfmusp.relation.reference | Giometto B, 2010, ARCH NEUROL-CHICAGO, V67, P330, DOI 10.1001/archneurol.2009.341 | eng |
hcfmusp.relation.reference | Granerod J, 2013, EMERG INFECT DIS, V19, P1455, DOI 10.3201/eid1909.130064 | eng |
hcfmusp.relation.reference | Granerod J, 2010, LANCET INFECT DIS, V10, P835, DOI 10.1016/S1473-3099(10)70222-X | eng |
hcfmusp.relation.reference | Graus F, 2004, J NEUROL NEUROSUR PS, V75, P1135, DOI 10.1136/jnnp.2003.034447 | eng |
hcfmusp.relation.reference | Graus F, 2001, BRAIN, V124, P1138, DOI 10.1093/brain/124.6.1138 | eng |
hcfmusp.relation.reference | Graus F, 2002, NEUROLOGY, V59, P764, DOI 10.1212/WNL.59.5.764 | eng |
hcfmusp.relation.reference | Graus F, 2016, LANCET NEUROL, V15, P391, DOI 10.1016/S1474-4422(15)00401-9 | eng |
hcfmusp.relation.reference | Graus F, 2014, BLOOD, V123, P3230, DOI 10.1182/blood-2014-03-537506 | eng |
hcfmusp.relation.reference | Gresa-Arribas N, 2014, LANCET NEUROL, V13, P167, DOI 10.1016/S1474-4422(13)70282-5 | eng |
hcfmusp.relation.reference | Gultekin SH, 2000, BRAIN, V123, P1481, DOI 10.1093/brain/123.7.1481 | eng |
hcfmusp.relation.reference | Hoftberger R, 2015, NEUROLOGY, V84, P2403, DOI 10.1212/WNL.0000000000001682 | eng |
hcfmusp.relation.reference | Hoftberger R, 2013, NEUROLOGY, V81, P1500, DOI 10.1212/WNL.0b013e3182a9585f | eng |
hcfmusp.relation.reference | Honnorat J, 2009, J NEUROL NEUROSUR PS, V80, P412, DOI 10.1136/jnnp.2007.138016 | eng |
hcfmusp.relation.reference | Honnorat J, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-22 | eng |
hcfmusp.relation.reference | Iorio R, 2013, J NEUROIMMUNOL, V263, P155, DOI 10.1016/j.jneuroim.2013.07.015 | eng |
hcfmusp.relation.reference | Irani SR, 2010, BRAIN, V133, P2734, DOI 10.1093/brain/awq213 | eng |
hcfmusp.relation.reference | KINSBOURNE M, 1962, J NEUROL NEUROSUR PS, V25, P271, DOI 10.1136/jnnp.25.3.271 | eng |
hcfmusp.relation.reference | Klaas JP, 2012, ARCH NEUROL-CHICAGO, V69, P1598, DOI 10.1001/archneurol.2012.1173 | eng |
hcfmusp.relation.reference | Lai MZ, 2010, LANCET NEUROL, V9, P776, DOI 10.1016/S1474-4422(10)70137-X | eng |
hcfmusp.relation.reference | Lai MZ, 2009, ANN NEUROL, V65, P424, DOI 10.1002/ana.21589 | eng |
hcfmusp.relation.reference | Lancaster E, 2011, NEUROLOGY, V77, P1698, DOI 10.1212/WNL.0b013e3182364a44 | eng |
hcfmusp.relation.reference | Lancaster Eric, 2015, Continuum (Minneap Minn), V21, P452, DOI 10.1212/01.CON.0000464180.89580.88 | eng |
hcfmusp.relation.reference | Lancaster E, 2012, NAT REV NEUROL, V8, P380, DOI 10.1038/nrneurol.2012.99 | eng |
hcfmusp.relation.reference | Lancaster E, 2011, ANN NEUROL, V69, P303, DOI 10.1002/ana.22297 | eng |
hcfmusp.relation.reference | Lancaster E, 2010, LANCET NEUROL, V9, P67, DOI 10.1016/S1474-4422(09)70324-2 | eng |
hcfmusp.relation.reference | Leypoldt F, 2015, ANN NY ACAD SCI, V1338, P94, DOI 10.1111/nyas.12553 | eng |
hcfmusp.relation.reference | Lopez-Chiriboga AS, 2016, NEUROLOGY, V86, P1009, DOI 10.1212/WNL.0000000000002476 | eng |
hcfmusp.relation.reference | Marignier R, 2010, ARCH NEUROL-CHICAGO, V67, P627, DOI 10.1001/archneurol.2010.51 | eng |
hcfmusp.relation.reference | Mason WP, 1997, BRAIN, V120, P1279, DOI 10.1093/brain/120.8.1279 | eng |
hcfmusp.relation.reference | Mathew RM, 2007, NEUROLOGY, V68, P900, DOI 10.1212/01.wnl.0000252379.81933.80 | eng |
hcfmusp.relation.reference | Murinson BB, 2008, NEUROLOGY, V71, P1955, DOI 10.1212/01.wnl.0000327342.58936.e0 | eng |
hcfmusp.relation.reference | Pellkofer H, 2004, BRAIN, V127, P1822, DOI 10.1093/brain/awh205 | eng |
hcfmusp.relation.reference | Petit-Pedrol M, 2014, LANCET NEUROL, V13, P276, DOI 10.1016/S1474-4422(13)70299-0 | eng |
hcfmusp.relation.reference | Rosenfeld Myrna R, 2012, Neurol Clin Pract, V2, P215 | eng |
hcfmusp.relation.reference | Rosenfeld Myrna R, 2012, Continuum (Minneap Minn), V18, P366, DOI 10.1212/01.CON.0000413664.42798.aa | eng |
hcfmusp.relation.reference | Sabater L, 2014, LANCET NEUROL, V13, P575, DOI [10.1016/S1474-4421(14)70051-1, 10.1016/S1474-4422(14)70051-1] | eng |
hcfmusp.relation.reference | Sabater L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060438 | eng |
hcfmusp.relation.reference | Sahu Jitendra Kumar, 2011, Pract Neurol, V11, P160, DOI 10.1136/practneurol-2011-000017 | eng |
hcfmusp.relation.reference | Saiz A, 2009, J NEUROL NEUROSUR PS, V80, P404, DOI 10.1136/jnnp.2008.158246 | eng |
hcfmusp.relation.reference | Saiz A, 2008, BRAIN, V131, P2553, DOI 10.1093/brain/awn183 | eng |
hcfmusp.relation.reference | Schmitt SE, 2012, NEUROLOGY, V79, P1094, DOI 10.1212/WNL.0b013e3182698cd8 | eng |
hcfmusp.relation.reference | Simabukuro MM, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000073 | eng |
hcfmusp.relation.reference | Smitt PS, 1996, J NEUROIMMUNOL, V71, P199, DOI 10.1016/S0165-5728(96)00153-1 | eng |
hcfmusp.relation.reference | Smitt PS, 2000, NEW ENGL J MED, V342, P21, DOI 10.1056/NEJM200001063420104 | eng |
hcfmusp.relation.reference | Titulaer MJ, 2011, EUR J NEUROL, V18, P19, DOI 10.1111/j.1468-1331.2010.03220.x | eng |
hcfmusp.relation.reference | Titulaer MJ, 2013, LANCET NEUROL, V12, P157, DOI 10.1016/S1474-4422(12)70310-1 | eng |
hcfmusp.relation.reference | TROTTER JL, 1976, ARCH NEUROL-CHICAGO, V33, P660, DOI 10.1001/archneur.1976.00500090066014 | eng |
hcfmusp.relation.reference | van Sonderen A, 2016, NEUROLOGY, V87, P1449 | eng |
hcfmusp.relation.reference | van Sonderen A, 2016, NEUROLOGY, V87, P521, DOI 10.1212/WNL.0000000000002917 | eng |
hcfmusp.relation.reference | Vedeler CA, 2006, EUR J NEUROL, V13, P682, DOI 10.1111/j.1468-2006.01266.x | eng |
hcfmusp.relation.reference | Vitaliani R, 2005, ANN NEUROL, V58, P594, DOI 10.1002/ana.20614 | eng |
hcfmusp.relation.reference | Voltz R, 1998, NEUROLOGY, V51, P1146, DOI 10.1212/WNL.51.4.1146 | eng |
hcfmusp.relation.reference | Vora NM, 2014, NEUROLOGY, V82, P443, DOI 10.1212/WNL.0000000000000086 | eng |
hcfmusp.relation.reference | WHITELEY AM, 1976, BRAIN, V99, P27, DOI 10.1093/brain/99.1.27 | eng |
hcfmusp.relation.reference | WILKINSO.PC, 1965, BRAIN, V88, P529, DOI 10.1093/brain/88.3.529 | eng |
hcfmusp.relation.reference | Wirtz PW, 2005, J NEUROIMMUNOL, V164, P161, DOI 10.1016/j.jneuroim.2005.04.001 | eng |
dc.description.index | MEDLINE | eng |
dc.identifier.eissn | 1534-6269 | |
hcfmusp.citation.scopus | 59 | - |
hcfmusp.scopus.lastupdate | 2024-04-12 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MNE Artigos e Materiais de Revistas Científicas - HC/ICESP Artigos e Materiais de Revistas Científicas - HC/ICHC Artigos e Materiais de Revistas Científicas - LIM/15 Artigos e Materiais de Revistas Científicas - LIM/45 Artigos e Materiais de Revistas Científicas - ODS/03 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_GRATIVVOL_Updates_in_the_Diagnosis_and_Treatment_of_Paraneoplastic_2018.PDF Restricted Access | publishedVersion (English) | 469.99 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.